This is a summary of the European public assessment report (EPAR) for Cinqaero. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Cinqaero. For practical information about using Cinqaero, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Cinqaero is indicated as add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.
Therapeutic Area (MeSH)
ATC Code
R03DX08
ATC Item
reslizumab
Pharmacotherapeutic Group
Other systemic drugs for obstructive airway diseases
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| Reslizumab | N/A | 斯普利珠单抗 |
EMA Name
Cinqaero
Medicine Name
Cinqaero
Aliases
N/ANo risk management plan link.
